[Comment] FLT3 inhibition in acute myeloid leukaemia

FLT3 is a transmembrane tyrosine kinase that stimulates survival and proliferation of leukaemic blasts. The two main FLT3 mutations found in acute myeloid leukaemia are internal tandem duplications in the juxtamembrane domain (roughly 30% of mutations) and point mutations in the tyrosine kinase domain loop at the Asp835 codon (D835; roughly 7–10%).1 Patients with newly diagnosed acute myeloid leukaemia and internal tandem duplications in FLT3 who are treated with conventional chemotherapy have poorer outcomes (3-year survival <20%) than do patients without these mutations (3-year survival 45–55%), because of their increased risk of relapse and inferior event-free survival.

http://ift.tt/2v0JhE1